Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS‐APSEC study: a discrete choice experiment
| Autor: | Protiere, Christel, Arnold, Michael, Fiorentino, Marion, Fressard, Lisa, Lelièvre, Jean D, Mimi, Mohamed, Raffi, François, Mora, Marion, Meyer, Laurence, Sagaon‐Teyssier, Luis, Zucman, David, Préau, Marie, Lambotte, Olivier, Spire, Bruno, Suzan‐Monti, Marie, Bergmann, J.F., Blacher, J., Blanc, A.P., Delobel, P., Girard, P.M., Goujard, C., Katlama, C., De Lacroix, I., Lafeuillade, A., Lelièvre, J.D., Lepeu, G., Michelet, C., Molina, J.M., Morlat, P., Peyramond, D., Piroth, L., Poizot‐Martin, I., Raffi, F., Ragnaud, J.M., Senneville, E., Weiss, L., Yazdanpanh, Y., Zucman, D. |
|---|---|
| Přispěvatelé: | COMBE, Isabelle, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Informing Change [Berkeley, CA, USA], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Médecine Interne [Hôpital Foch, Suresnes] (SMI), Hôpital Foch [Suresnes], Groupe de Recherche en Psychologie Sociale (GRePS), Université Lumière - Lyon 2 (UL2), Service de médecine interne et maladies infectieuses, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Infectious Diseases Models for Innovative Therapies (IDMIT), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Institut des Maladies Emergentes et des Thérapies Innovantes (IMETI), The ANRS-APSEC survey was supported by a grant (convention number 14697) from ANRS (France Recherche Nord & sud Sida-hiv Hépatites)., APSEC Study Group : Bergmann JF, Blacher J, Blanc AP, Delobel P, Girard PM, Goujard C, Katlama C, De Lacroix I, Lafeuillade A, Lelièvre JD, Lepeu G, Michelet C, Molina JM, Morlat P, Peyramond D, Piroth L, Poizot-Martin I, Raffi F, Ragnaud JM, Senneville E, Weiss L, Yazdanpanh Y, Zucman D., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA) |
| Rok vydání: | 2020 |
| Předmět: |
Male
mixed logit model Human immunodeficiency virus (HIV) HIV Infections Discrete choice experiment medicine.disease_cause Choice Behavior 0302 clinical medicine [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Mixed logit Informed consent clinical trial design recommendations 030212 general & internal medicine Research Articles preferences [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases Clinical Trials as Topic [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases Ethical issues Middle Aged [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system 3. Good health Infectious Diseases therapeutic HIV vaccine trial [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases Female France 0305 other medical science social sciences [SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology Research Article medicine.medical_specialty HIV eradication/remission Affect (psychology) 03 medical and health sciences [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system Physicians medicine Humans [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology 030505 public health business.industry discrete choice experiment Public Health Environmental and Occupational Health ethics [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology Clinical trial Family medicine Combined therapy [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology business |
| Zdroj: | Journal of the International AIDS Society Journal of the International AIDS Society, 2020, 23 (2), pp.e25443. ⟨10.1002/jia2.25443⟩ Journal of the International AIDS Society, BioMed Central (2008-2012) ; International Aids Society (2008-) ; Wiley (2017-), 2020, 23 (2), pp.e25443. ⟨10.1002/jia2.25443⟩ |
| ISSN: | 1758-2652 |
| DOI: | 10.1002/jia2.25443 |
| Popis: | International audience; INTRODUCTION:Despite the advent of HIV cure-related clinical trials (HCRCT) for people living with HIV (PLWH), the risks and uncertainty involved raise ethical issues. Although research has provided insights into the levers and barriers to PLWH and physicians' participation in these trials, no information exists about stakeholders' preferences for HCRCT attributes, about the different ways PLWH and physicians value future HCRCT, or about how personal characteristics affect these preferences. The results from the present study will inform researchers' decisions about the most suitable HCRCT strategies to implement, and help them ensure ethical recruitment and well-designed informed consent.METHODS:Between October 2016 and March 2017, a discrete choice experiment was conducted among 195 virally controlled PLWH and 160 physicians from 24 French HIV centres. Profiles within each group, based on individual characteristics, were obtained using hierarchical clustering. Trade-offs between five HCRCT attributes (trial duration, consultation frequency, moderate (digestive disorders, flu-type syndrome, fatigue) and severe (allergy, infections, risk of cancer) side effects (SE), outcomes) and utilities associated with four HCRCT candidates (latency reactivation, immunotherapy, gene therapy and a combination of latency reactivation and immunotherapy), were estimated using a mixed logit model.RESULTS:Apart from severe SE - the most decisive attribute in both groups - PLWH and physicians made different trade-offs between HCRCT attributes, the latter being more concerned about outcomes, the former about the burden of participation (consultation frequency and moderate SE). These different trades-offs resulted in differences in preferences regarding the four candidate HCRCT. PLWH significantly preferred immunotherapy, whereas physicians preferred immunotherapy and combined therapy. Despite the heterogeneity of characteristics within the PLWH and physician profiles, results show some homogeneity in trade-offs and utilities regarding HCRCT.CONCLUSIONS:Severe SE, not outcomes, was the most decisive attribute determining future HCRCT participation. Particular attention should be paid to providing clear information, in particular on severe SE, to potential participants. Immunotherapy would appear to be the best HCRCT candidate for both PLWH and physicians. However, if the risk of cancer could be avoided, gene therapy would become the preferred strategy for the latter and the second choice for the former. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|